Gail Farfel

Insider profile

Currently holds positions in Zogenix Inc and DURECT Corp

Performance

Overall performance
3.7
Performance over holding periods
3.7
30 days 90 days 120 days
Average return 29% 8.2% 15.1%
Success rate 89% 68% 82%
Transactions
10 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Executive Vice President, Chief Development Officer Zogenix Inc July 6, 2015 -
Independent Director DURECT Corp April 23, 2019 -
Chief Clinical Development and Regulatory Officer Marinus Pharmaceuticals Inc Dec. 1, 2012 - Jan. 1, 2015
Gail Farfel's trades of ProMIS Neurosciences Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
189.59
Quantity 87,138 +39.5%
Value US$3,561,495
Transaction date
Purchase
Price
125.35
Quantity 71,131 -3.5%
Value US$2,554,282
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
115.49
Quantity 54,588 +5.8%
Value US$4,243,897
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.39
Quantity 25,300 +56.5%
Value US$9,811
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.40
Quantity 9,250 +26.0%
Value US$3,700
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.39
Quantity 1,500 +4.4%
Value US$585
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.40
Quantity 9,950 +41.3%
Value US$3,973
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.41
Quantity 2,339 +10.8%
Value US$950
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.40
Quantity 4,250 +24.3%
Value US$1,679
US DURECT Corp (DRRX)
Transaction date
Purchase
Price
0.39
Quantity 17,500 New position
Value US$6,906
US Zogenix Inc (ZGNX)
Transaction date
Planned sale
Price
28.21
Quantity 2,573 -33.8%
Value US$72,584
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-12-16 2022-12-14
B Purchase
87,138 +39.5%
189.59
US$3,561,495 		87,138 +39.5% 189.59 US$3,561,495
2022-12-08 2022-12-06
B Purchase
71,131 -3.5%
125.35
US$2,554,282 		71,131 -3.5% 125.35 US$2,554,282
2022-05-18 2022-05-18
US DURECT Corp (DRRX)
B Purchase
54,588 +5.8%
115.49
US$4,243,897 		54,588 +5.8% 115.49 US$4,243,897
2022-05-18 2022-05-16
US DURECT Corp (DRRX)
B Purchase
25,300 +56.5%
0.39
US$9,811 		25,300 +56.5% 0.39 US$9,811
2022-05-13 2022-05-13
US DURECT Corp (DRRX)
B Purchase
9,250 +26.0%
0.40
US$3,700 		9,250 +26.0% 0.40 US$3,700
2022-05-13 2022-05-12
US DURECT Corp (DRRX)
B Purchase
1,500 +4.4%
0.39
US$585 		1,500 +4.4% 0.39 US$585
2022-05-13 2022-05-11
US DURECT Corp (DRRX)
B Purchase
9,950 +41.3%
0.40
US$3,973 		9,950 +41.3% 0.40 US$3,973
2022-05-12 2022-05-10
US DURECT Corp (DRRX)
B Purchase
2,339 +10.8%
0.41
US$950 		2,339 +10.8% 0.41 US$950
2022-05-10 2022-05-10
US DURECT Corp (DRRX)
B Purchase
4,250 +24.3%
0.40
US$1,679 		4,250 +24.3% 0.40 US$1,679
2022-05-10 2022-05-09
US DURECT Corp (DRRX)
B Purchase
17,500 New position
0.39
US$6,906 		17,500 New position 0.39 US$6,906
2020-05-13 2020-05-12
US Zogenix Inc (ZGNX)
PlS Planned sale
2,573 -33.8%
28.21
US$72,584 		2,573 -33.8% 28.21 US$72,584
2015-04-23 2015-04-21
PlS Planned sale
30,000 -100.0%
9.48
US$284,511 		30,000 -100.0% 9.48 US$284,511